These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28700554)

  • 21. Eek, a XenoMouse: Abgenix, Inc.
    Wells WA
    Chem Biol; 2000 Aug; 7(8):R185-6. PubMed ID: 11048946
    [No Abstract]   [Full Text] [Related]  

  • 22. A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
    Udata C; Garzone PD; Gumbiner B; Joh T; Liang H; Liao KH; Williams JH; Meng X
    J Clin Pharmacol; 2017 Jul; 57(7):855-864. PubMed ID: 28181260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
    Ridker PM; Tardif JC; Amarenco P; Duggan W; Glynn RJ; Jukema JW; Kastelein JJP; Kim AM; Koenig W; Nissen S; Revkin J; Rose LM; Santos RD; Schwartz PF; Shear CL; Yunis C;
    N Engl J Med; 2017 Apr; 376(16):1517-1526. PubMed ID: 28304227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody engineering--IBC's 15th Annual International Conference. 30 November-3 December 2004, San Diego, CA, USA.
    Haurum JS
    IDrugs; 2005 Feb; 8(2):91-3. PubMed ID: 15696403
    [No Abstract]   [Full Text] [Related]  

  • 25. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of molecular imaging on validation of developed anti-hVEGFR2 therapeutic antibody.
    Cheong SJ; Lee CM; Jang D; Kim EM; Jeong MH; Uhm TB; Lee WS; Jeong HJ; Kim DW; Lim ST; Sohn MH
    Cancer Biother Radiopharm; 2011 Dec; 26(6):745-51. PubMed ID: 22003972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prokaryotic expression and characterization of an anti-KDR single chain antibody].
    Li R; Xiong DS; Xu YF; Shao XF; Fan DM; Zhu ZP; Yang CZ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jan; 21(1):39-42. PubMed ID: 15629080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
    Kołodziejczak M; Navarese EP
    Atherosclerosis; 2016 Apr; 247():189-92. PubMed ID: 26926598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience.
    Farnier M
    Curr Opin Lipidol; 2016 Dec; 27(6):597-604. PubMed ID: 27755114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Progress of research on genetic engineering antibody and its application in prevention and control of parasitic diseases].
    Yao Y; Yu CX
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2013 Aug; 25(4):413-6. PubMed ID: 24358756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia.
    Li B; Hao PP; Zhang Y; Yin RH; Kong QZ; Cai XJ; Zhao Z; Qi JN; Li Y; Xiao J; Wang F; Yi W; Ji XP; Su GH
    Oncotarget; 2017 May; 8(18):30455-30463. PubMed ID: 27458166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of humanized rabbit monoclonal antibodies against vascular endothelial growth factor receptor 2 with potential antitumor effects.
    Yu Y; Lee P; Ke Y; Zhang Y; Chen J; Dai J; Li M; Zhu W; Yu GL
    Biochem Biophys Res Commun; 2013 Jul; 436(3):543-50. PubMed ID: 23770369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody Engineering--IBC's 17th annual international conference. Antibody engineering and immunotherapeutics for the 21st century.
    Bradbury A
    IDrugs; 2007 Mar; 10(3):169-72. PubMed ID: 17351868
    [No Abstract]   [Full Text] [Related]  

  • 38. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.
    Chackerian B; Remaley A
    Curr Opin Lipidol; 2016 Aug; 27(4):345-50. PubMed ID: 27389630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
    Knod L; Donovan EC; Chernoguz A; Crawford KM; Dusing MR; Frischer JS
    J Surg Res; 2013 Sep; 184(1):101-7. PubMed ID: 23688787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The biotechnology and applications of antibody engineering.
    Rapley R
    Mol Biotechnol; 1995 Apr; 3(2):139-54. PubMed ID: 7620975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.